Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunoconjugates: current status and future potential.

M Eaton

    Journal of Drug Targeting
    |April 10, 2003
    PubMed
    Summary
    This summary is machine-generated.

    Biotechnology advancements in the 1980s enabled the creation of pure immunoconjugates for clinical studies. Early challenges with antibody immunogenicity were overcome through chimeric and humanized antibodies, fostering industrial interest.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.

    Annals of oncology : official journal of the European Society for Medical Oncology·2026
    Same author

    A novel PIGA variant associated with severe X-linked epilepsy and profound developmental delay.

    Seizure·2018
    Same author

    Challenges in the design of clinically useful brain-targeted drug nanocarriers.

    Current medicinal chemistry·2014
    Same author

    Molecular analysis of intragenic recombination at the tryptophan synthetase locus in Neurospora crassa.

    Journal of genetics·2013
    Same author

    Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer·2013
    Same author

    Porcine reproductive and respiratory syndrome virus productively infects monocyte-derived dendritic cells and compromises their antigen-presenting ability.

    Archives of virology·2006

    Area of Science:

    • Biotechnology and Pharmaceutical Sciences
    • Immunology and Drug Delivery

    Background:

    • The concept of immunoconjugates dates back two centuries, but practical application was limited until the 1980s.
    • Biotechnology advancements provided the necessary tools to produce pure immunoconjugates in clinically relevant quantities.

    Discussion:

    • Early immunoconjugate development faced challenges with antibody immunogenicity.
    • Chimeric and humanized antibodies were developed to mitigate these immunogenicity issues.
    • Significant industrial investment, particularly from biotechnology firms, fueled the evaluation of various immunoconjugate approaches.

    Key Insights:

    • The 1980s marked a pivotal era for immunoconjugate development due to technological breakthroughs.
    • Overcoming antibody immunogenicity was crucial for the clinical viability of immunoconjugates.

    Related Experiment Videos

  • Strong industrial backing accelerated research and development in the field.

    • Outlook:

    • Continued innovation in antibody engineering and conjugation technologies is expected.
    • Further exploration of diverse immunoconjugate strategies will likely emerge.
    • The synergy between academic research and biotechnology industry will drive future progress.